CLAIMS

1. Association of *N*-{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, with perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms, for use in the treatment of heart failure with preserved systolic function, wherein said treatment comprises a simultaneous administration of:

N-{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms; and

perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms to a subject.

2. Association according to claim 1, characterised in that *N-{[(*7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine is in the form of a hydrochloride or a fumarate, or one of its hydrates or crystalline forms.

3. Association according to one of claims 1 or 2, characterised in that the perindopril is in the form of a *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

4. Association according to claim 1, characterised in that *N-{[(*7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine is in the form of a hydrochloride or a fumarate or one of its hydrates or crystalline forms, and

perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

5. Pharmaceutical compositions comprising as active ingredients:

- *N*-*{[(*7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, and
- perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms,

on their own or in combination with one or more pharmaceutically acceptable excipients, for use in the treatment of heart failure with preserved systolic function.

6. Pharmaceutical composition according to claim 5, characterised in that *N*-*{[(*7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine is in the form of a hydrochloride or a fumarate, or one of its hydrates or crystalline forms.

7. Pharmaceutical composition according to claim 5, characterised in that perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

8. Pharmaceutical composition according to claim 5, characterised in that *N*-*{[(*7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine is in the form of a hydrochloride or a fumarate, or one of its hydrates or crystalline forms, and perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.